In March 2024, received FDA approval of its product, sotatercept (WINREVAIR), for the treatment of adults with PAH. In August 2024, announced that the European Commission approved sotatercept for the treatment of adults with PAH. All of the other currently-approved therapies for PAH are vasodilators, which are medications that dilate blood vessels.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

Merck & Co Inc

Developing seralutinib for the treatment of PAH.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

Gossamer Bio Inc

Markets EMFLAZA (deflazacort), an FDA-approved corticosteroid for the treatment of DMD.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

PTC Therapeutics Inc

Markets FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are phosphorodiamidate morpholino oligomers, or PMOs, approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively. Additionally, in June 2023, announced that the FDA accelerated approval of its product, ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

Sarepta Therapeutics Inc

Developing gene therapies to treat DMD.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

Pfizer Inc

Solid Biosciences Inc

Pursuing gene editing treatments that are in preclinical development for DMD.  **[0001664710-25-000018_kros-20241231.htm:35]** **[0001664710-25-000018_kros-20241231.htm:98]** 

Vertex Pharmaceuticals Inc

Developing product candidates for the treatment of anemia.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

FibroGen Inc

Developing product candidates targeting diseases associated with MDS and myelofibrosis, including chronic anemia. In April 2020, received FDA approval of its product, Reblozyl, for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

Bristol-Myers Squibb Co

In June 2024, announced that the FDA approved imetelstat (RYTELO) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

Geron Corp

In September 2023, announced that the FDA approved its product, Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

GSK plc

Developing an ALK2 inhibitor product candidate for the treatment of myelofibrosis.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

Incyte Corp

Developing product candidates that are designed to target the TGF-ß signaling pathways.  **[0001664710-25-000018_kros-20241231.htm:36]** **[0001664710-25-000018_kros-20241231.htm:99]** 

Organization	Role	Date Range	Details
Ember Therapeutics, Inc.	Chief Scientific Officer	Dec 2011 - Apr 2015	N/A
Eloxx Pharmaceuticals, Inc.	Board Member	N/A	Previously served as board member
Acceleron Pharma Inc.	Co-Founder and Chief Scientific Officer	Feb 2004 - Nov 2010	N/A
Wyeth Pharmaceuticals Inc.	Vice President of Biological Chemistry	N/A	Led the small molecule lead discovery effort at Genetics Institute, Inc.
Genetics Institute, Inc.	Leadership in Small Molecule Drug Discovery	N/A	Helped build capabilities in medicinal chemistry, high throughput screening, and structural biology

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$699,039	Regular payroll	2024 base salary
Bonus	$0	N/A	No bonus awarded
Option Awards (Time-Vesting)	125,000 shares, Fair Value: $5,104,488, Exercise Price: $56.18 per share	Time-vesting; Granted on February 13, 2024	Share-based, time-vesting equity component
All Other Compensation	$14,666	Lump sum	Includes 401(k) match of $9,900 and cell phone expense reimbursement of $4,766

Detail	Value
Grant Date	February 23, 2024
Exercise Price	$63.61 per share
Grant Date Fair Value	$4,875,900
Performance Metrics	Two development goals for cibotercept and KER-065
Performance Period	Through December 31, 2025
Vesting Schedule	50% of eligible shares upon certification; remaining 50% on December 31, 2026
Acceleration Conditions	Full acceleration upon change of control OR continuation for 12 months post involuntary termination

Detail	Value
Awarded Amount	$455,000
Target Bonus Percentage	Increased from 50% to 65% of base salary
Achieved Performance	110% achievement, capped at 100% payout
Payout Conditions	Contingent upon achieving annual performance goals
Additional Details	No specific thresholds, metrics, vesting schedules, or grant dates provided

Jasbir Seehra

Also at Keros Therapeutics

About

$KROS Performance Under Jasbir Seehra

Past Roles

External Roles

Fixed Compensation

Performance Compensation

Performance-Vesting Stock Option

Non-Equity Incentive Plan Compensation